PDSB
Price
$1.06
Change
+$0.01 (+0.95%)
Updated
Sep 24, 12:21 PM (EDT)
Capitalization
49.38M
49 days until earnings call
VRDN
Price
$19.48
Change
-$0.08 (-0.41%)
Updated
Sep 24, 12:35 PM (EDT)
Capitalization
1.6B
55 days until earnings call
Interact to see
Advertisement

PDSB vs VRDN

Header iconPDSB vs VRDN Comparison
Open Charts PDSB vs VRDNBanner chart's image
PDS Biotechnology
Price$1.06
Change+$0.01 (+0.95%)
Volume$150
Capitalization49.38M
Viridian Therapeutics
Price$19.48
Change-$0.08 (-0.41%)
Volume$600
Capitalization1.6B
PDSB vs VRDN Comparison Chart in %
Loading...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PDSB vs. VRDN commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PDSB is a Hold and VRDN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (PDSB: $1.05 vs. VRDN: $19.56)
Brand notoriety: PDSB and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PDSB: 79% vs. VRDN: 59%
Market capitalization -- PDSB: $49.38M vs. VRDN: $1.6B
PDSB [@Biotechnology] is valued at $49.38M. VRDN’s [@Biotechnology] market capitalization is $1.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PDSB’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • PDSB’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, both PDSB and VRDN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PDSB’s TA Score shows that 3 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • PDSB’s TA Score: 3 bullish, 6 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than PDSB.

Price Growth

PDSB (@Biotechnology) experienced а -12.50% price change this week, while VRDN (@Biotechnology) price change was +4.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +53.86%.

Reported Earning Dates

PDSB is expected to report earnings on Nov 12, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.6B) has a higher market cap than PDSB($49.4M). VRDN YTD gains are higher at: 2.034 vs. PDSB (-35.583). PDSB has higher annual earnings (EBITDA): -32.36M vs. VRDN (-340.62M). VRDN has more cash in the bank: 563M vs. PDSB (31.9M). PDSB has less debt than VRDN: PDSB (18.5M) vs VRDN (21.3M). VRDN has higher revenues than PDSB: VRDN (305K) vs PDSB (0).
PDSBVRDNPDSB / VRDN
Capitalization49.4M1.6B3%
EBITDA-32.36M-340.62M10%
Gain YTD-35.5832.034-1,749%
P/E RatioN/AN/A-
Revenue0305K-
Total Cash31.9M563M6%
Total Debt18.5M21.3M87%
FUNDAMENTALS RATINGS
PDSB vs VRDN: Fundamental Ratings
PDSB
VRDN
OUTLOOK RATING
1..100
1775
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
9145
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5018

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (30) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRDN (94) in the Biotechnology industry. This means that PDSB’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to PDSB’s over the last 12 months.

VRDN's SMR Rating (99) in the Biotechnology industry is in the same range as PDSB (99) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to PDSB’s over the last 12 months.

VRDN's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for PDSB (91) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew somewhat faster than PDSB’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PDSBVRDN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 22 days ago
86%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 13 days ago
89%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TV2.790.02
+0.72%
Grupo Televisa SA
NVEC67.090.09
+0.13%
NVE Corp
MXGBF51.16N/A
N/A
Molson Coors CDA Inc.
PNFP95.08-0.10
-0.11%
Pinnacle Financial Partners
BTAI2.47-0.31
-11.15%
BioXcel Therapeutics Inc

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with DYN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-2.78%
DYN - PDSB
44%
Loosely correlated
-1.86%
VRDN - PDSB
42%
Loosely correlated
+0.05%
IDYA - PDSB
42%
Loosely correlated
+0.04%
RGNX - PDSB
42%
Loosely correlated
-1.43%
ARCT - PDSB
42%
Loosely correlated
-3.66%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+0.05%
SYRE - VRDN
58%
Loosely correlated
+4.77%
CRNX - VRDN
56%
Loosely correlated
+6.35%
NUVL - VRDN
55%
Loosely correlated
+2.76%
OCUL - VRDN
52%
Loosely correlated
+0.41%
BEAM - VRDN
52%
Loosely correlated
-2.79%
More